A detailed history of Price T Rowe Associates Inc transactions in Immuneering Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 859,374 shares of IMRX stock, worth $1.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
859,374
Previous 910,266 5.59%
Holding current value
$1.6 Million
Previous $2.63 Million 58.21%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.28 - $2.75 $65,141 - $139,953
-50,892 Reduced 5.59%
859,374 $1.1 Million
Q1 2024

May 15, 2024

SELL
$1.91 - $7.32 $4.71 Million - $18.1 Million
-2,467,834 Reduced 73.05%
910,266 $2.63 Million
Q4 2023

Feb 14, 2024

SELL
$4.84 - $8.44 $751,274 - $1.31 Million
-155,222 Reduced 4.39%
3,378,100 $24.8 Million
Q3 2023

Nov 14, 2023

SELL
$7.21 - $10.68 $341,919 - $506,477
-47,423 Reduced 1.32%
3,533,322 $27.1 Million
Q2 2023

Aug 14, 2023

BUY
$6.49 - $13.36 $794,226 - $1.63 Million
122,377 Added 3.54%
3,580,745 $36.3 Million
Q1 2023

May 15, 2023

SELL
$3.78 - $10.38 $609,305 - $1.67 Million
-161,192 Reduced 4.45%
3,458,368 $33.6 Million
Q4 2022

Feb 14, 2023

SELL
$4.09 - $15.0 $179,681 - $658,980
-43,932 Reduced 1.2%
3,619,560 $17.6 Million
Q3 2022

Nov 14, 2022

SELL
$5.0 - $14.32 $2.4 Million - $6.86 Million
-479,337 Reduced 11.57%
3,663,492 $52.5 Million
Q2 2022

Aug 15, 2022

BUY
$3.89 - $7.81 $2.25 Million - $4.51 Million
577,356 Added 16.19%
4,142,829 $22.4 Million
Q1 2022

May 16, 2022

BUY
$6.47 - $16.99 $2.44 Million - $6.4 Million
376,968 Added 11.82%
3,565,473 $23.1 Million
Q4 2021

Feb 14, 2022

BUY
$16.12 - $31.02 $1.2 Million - $2.31 Million
74,480 Added 2.39%
3,188,505 $50.7 Million
Q3 2021

Nov 15, 2021

BUY
$17.0 - $32.84 $52.9 Million - $102 Million
3,114,025 New
3,114,025 $81.2 Million

Others Institutions Holding IMRX

About Immuneering Corp


  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $49.1M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.